Leading pharma company Ranbaxy Laboratories has strengthened its presence in the cancer drug segment through an exclusive in-licensing agreement with Australian drug manufacturer Sirtex Medical.
Ranbaxy will market Sirtex's liver cancer medicine, SIR-Spheres, in India, Bangladesh, Sri Lanka and Nepal.
The product, approved by the US Food and Drug Administration, is used on patients with inoperable tumours.
Ranbaxy had earlier tied up with Hyderabad based Zenotech to market its oncology products in the US and Canada.
Sanjeev Dani, senior vice-president and